Last reviewed · How we verify
Herpes Zoster vaccine GSK1437173A Modified
Herpes Zoster vaccine GSK1437173A Modified is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | Herpes Zoster vaccine GSK1437173A Modified |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Herpes Zoster vaccine GSK1437173A Modified CI brief — competitive landscape report
- Herpes Zoster vaccine GSK1437173A Modified updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Herpes Zoster vaccine GSK1437173A Modified
What is Herpes Zoster vaccine GSK1437173A Modified?
Herpes Zoster vaccine GSK1437173A Modified is a Biologic drug developed by GlaxoSmithKline.
Who makes Herpes Zoster vaccine GSK1437173A Modified?
Herpes Zoster vaccine GSK1437173A Modified is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Herpes Zoster vaccine GSK1437173A Modified in?
Herpes Zoster vaccine GSK1437173A Modified is in Phase 2.